

Message

From: Lindstrom, Andrew [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=04BF7CF26AA44CE29763FBC1C1B2338E-LINDSTROM, ANDREW]
Sent: 6/20/2017 6:57:10 PM
To: Buckley, Timothy [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=197a3461d9824a17850f34cc2b0b37fe-Buckley, Timothy]; chris.johnson@ncdenr.gov; Allenbach, Becky [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fd8d7185973c44268441863f02a769d1-Allenbach, Becky]; Strynar, Mark [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5a9910d5b38e471497bd875fd329a20a-Strynar, Mark]; Medina-Vera, Myriam [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b081a1f48a044b4c9d1ebc4992c54dee-Medina-Vera, Myriam]; cyndi.karoly@ncdenr.gov; linda.culpepper@ncdenr.gov
CC: Jones, Nick [nick.jones@ncdenr.gov]; Perez, Helen I [helen.perez@ncdenr.gov]; Satterwhite, Dana [dana.satterwhite@ncdenr.gov]
Subject: RE: Discussion for sampling and analysis in Wilmington
Attachments: Field Sample Collection EMAB-113-0.pdf

All,

I've attached a copy of the field collection protocol that we have been using for PFAS compounds including GenX.

The shipping address and storage conditions are specified on page 6.

Please let us know if you have any questions.

Thank you very much,

Andy

-----Original Appointment-----

From: Buckley, Timothy
Sent: Tuesday, June 20, 2017 1:20 PM
To: chris.johnson@ncdenr.gov; Allenbach, Becky; Strynar, Mark; Medina-Vera, Myriam; cyndi.karoly@ncdenr.gov; linda.culpepper@ncdenr.gov
Cc: Lindstrom, Andrew; Jones, Nick; Perez, Helen I; Satterwhite, Dana
Subject: Discussion for sampling and analysis in Wilmington
When: Tuesday, June 20, 2017 2:00 PM-2:30 PM (UTC-05:00) Eastern Time (US & Canada).
Where: Teleconference: Personal Phone / Ex. 6

Thank you all for making time for this discussion. I know that there is a lot of pressure to move quickly on this project. ORD/NERL is happy to provide analytical support. To guide our involvement/effort, I am hoping that collectively we can provide answers to the following questions.

1. What question are we attempting to address with this sampling effort?
2. What is the sampling design?
3. What is the status and timeline of the QAPP?
4. Given split sample analysis (contract lab and NERL lab), how will differences in reported concentrations be managed?
5. What is the plan for communicating results and who has the lead?
6. What is the project timeline?
7. Do we need on-going coordination meetings?